Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age

              Author:Wiendl, Heinz   Cohen, Jeffrey   Gold, Ralf   De Seze, Jerome   Robertson, Derrick   Wray, Sibyl   Sacca, Francesco   Zielman, Ronald   Azmon, Amin   King, Miriam   Fantaccini, Simone   Kappos, Ludwig   

              Session Name:P6: MS Clinical Trials  

              Topic:MS and Inflammatory Disease  

              Program Number:P6.016  

              Author Institution:University of Muenster, Muenster, Germany  Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany  University Hospital of Strasbourg, Strasbourg, France  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL  Hope Neurology MS Center, Knoxville, TN  Department (NSRO), University “Federico II” of Naples, Naples, Italy  Novartis Pharma B.V., Amsterdam, Netherlands  Novartis Pharma AG, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland  

              Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis

              Author:Cohen, Jeffrey   Hauser, Stephen   Cross, Anne   Winthrop, Kevin   Wiendl, Heinz   Nicholas, Jacqueline   Meuth, Sven   Giacomini, Paul   Sacca, Francesco   Zielman, Ronald   Das Gupta, Ayan   Hu, Xixi   Sullivan, Roseanne   DeLasHeras, Virginia   Kappos, Ludwig   

              Session Name:P8: MS Therapeutics 2  

              Topic:MS and Inflammatory Disease  

              Program Number:P8.004  

              Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO  Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR  University of Muenster, Muenster, Germany, Muenster, Germany  OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH  Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada  NSRO Department, University “Federico II” of Naples, Naples, Italy, Napoli, Italy  Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland